+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer



Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer



Cancer ChemoTherapy and Pharmacology 79(3): 497-505



In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point mutation. The objective of this study was to evaluate whether body surface area (BSA), body weight (BW), and body mass index (BMI) affect gefitinib efficacy in such patients. The medical charts of 138 consecutive patients with advanced NSCLC harboring sensitive EGFR mutations, who underwent gefitinib treatment, were reviewed. The median BSA and BW were used as cutoff values to evaluate their impact on gefitinib efficacy. BMI was categorized as underweight (<18.5 kg/m2), normal (18.5-25 kg/m2), and overweight (≥25 kg/m2). The median BSA and BW were 1.48 m2 and 53 kg, respectively. The overall response rate, progression-free survival (PFS), and overall survival (OS) were 65.2%, 12.2, and 24.2 months, respectively. There were no significant differences in clinical outcomes according to BSA, BW, or BMI alone. Subgroup analysis based on the mutation type and BSA revealed no significant differences in PFS between the groups; however, the median OS in those with exon 19 deletion combined with low BSA was significantly favorable compared with the other groups. Gefitinib efficacy in patients with NSCLC harboring sensitive EGFR mutations did not differ according to BSA, BW, and BMI. However, OS was superior in patients with both the exon 19 deletion and low BSA.

(PDF emailed within 0-6 h: $19.90)

Accession: 059705657

Download citation: RISBibTeXText

PMID: 28168310

DOI: 10.1007/s00280-016-3232-2


Related references

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Thoracic Cancer 2019, 2019

Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. Cancer ChemoTherapy and Pharmacology 74(5): 939-946, 2015

Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist 20(8): 967-974, 2016

Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer ChemoTherapy and Pharmacology 76(2): 251-256, 2015

Body weight , body mass index and body surface area as predictors of survival on CAPD patients. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 326A, Sept, 1999

Contrast enhancement during hepatic computed tomography: effect of total body weight, height, body mass index, blood volume, lean body weight, and body surface area. Journal of Computer Assisted Tomography 37(2): 159-164, 2013

Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. Thoracic Cancer 7(1): 61-65, 2016

Contrast enhancement in cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity. American Journal of Roentgenology 190(3): 777-784, 2008

Contrast enhancement in cardiovascular MDCT effect of body weight, height, body surface area, body mass index, and obesity. American Journal Of Roentgenology0: 3, 777-784, 2008

Body size indices to determine iodine mass with contrast-enhanced multi-detector computed tomography of the upper abdomen: does body surface area outperform total body weight or lean body weight?. European Radiology 23(7): 1855-1861, 2014

Determination of height, weight, body mass index, and body surface area with a single abdominal CT image. Radiology 228(3): 857-863, 2003

Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area. Molecular and Clinical Oncology 2(4): 604-608, 2014

Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology 140(11): 1901-1909, 2015

Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interactive Cardiovascular and Thoracic Surgery 23(4): 560-566, 2017

Evaluation of body weight, body mass index, and body fat percentage changes in early stages of fixed orthodontic therapy. Journal of International Society of Preventive and Community Dentistry 6(4): 349-358, 2016